Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authori...
Gespeichert in:
| Veröffentlicht in: | Expert review of vaccines 2009-05, Vol.8 (5), p.607-618 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 5 |
| container_start_page | 607 |
| container_title | Expert review of vaccines |
| container_volume | 8 |
| creator | Barrett, P Noel Mundt, Wolfgang Kistner, Otfried Howard, M Keith |
| description | The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases. |
| doi_str_mv | 10.1586/erv.09.19 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_199924860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A226551884</galeid><sourcerecordid>A226551884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-e8d2c67e2c8c7af37e875a946ee3f6b9788cf85004f78bb4a76ab626856109fa3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqVw4A-giAOCQxY78WdvVUULUiUuwIGLNXHGrSsnXuxkq_57vMoiPoV8sGU9z8w7mqp6TsmGciXeYtptiN5Q_aA6ppKxRnWaPyxvJkVDuGJH1ZOcbwnpmObycXVEdaclo_K4-voFU6wthlBvA8wuprH2U70Da_2E9TbFYbGzj9NpPcadn67rOd5BGvLq2CXMS8Kmh4xDvfMJwg83P60eOQgZnx3uk-rzxbtP5--bq4-XH87PrhrLKZ0bVENrhcTWKivBdRKV5KCZQOyc6LVUyjrFCWFOqr5nIAX0ohWKC0q0g-6kerXWLWG_LZhnM_q8TwcTxiUbIamkTOgCvv4vSFsuJReE7NGXf6C3cUlTGcNQrXXLlCAF2qzQNQQ0fnJxTmDLGXD0Nk7ofPk_a1vBOVWKFeHNKtgUc07ozDb5EdK9ocTsN2nKJg3RpUdhXxwSLP2Iw0_ysLoCsBXYN04j3MUUBjPDfYjJJZisz6b7V93uN-0GIcw3FhL-MuJf1ncu7b1C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199924860</pqid></control><display><type>article</type><title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines</title><source>MEDLINE</source><source>Access via Taylor & Francis</source><creator>Barrett, P Noel ; Mundt, Wolfgang ; Kistner, Otfried ; Howard, M Keith</creator><creatorcontrib>Barrett, P Noel ; Mundt, Wolfgang ; Kistner, Otfried ; Howard, M Keith</creatorcontrib><description>The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.</description><identifier>ISSN: 1476-0584</identifier><identifier>EISSN: 1744-8395</identifier><identifier>DOI: 10.1586/erv.09.19</identifier><identifier>PMID: 19397417</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Animals ; Avian influenza ; Cell culture ; Cell Culture Techniques ; Cercopithecus aethiops ; Contamination ; continuous cell line ; Diploids ; Drug Approval ; emerging virus disease ; Epidemics ; Fear ; Humans ; Infection ; Influenza ; Influenza A Virus, H5N1 Subtype - immunology ; pandemics ; Pediatrics ; Rabies ; Rabies virus ; Rabies virus - immunology ; Reviews ; Rotavirus ; Rotavirus - immunology ; Smallpox ; Smallpox - immunology ; Smallpox vaccine ; Vaccines ; Vaccines, Attenuated - immunology ; Vaccines, Inactivated - immunology ; Vero ; Vero Cells ; viral vaccine ; Viral Vaccines - biosynthesis ; Viral Vaccines - genetics</subject><ispartof>Expert review of vaccines, 2009-05, Vol.8 (5), p.607-618</ispartof><rights>Expert Reviews Ltd 2009</rights><rights>COPYRIGHT 2009 Expert Reviews Ltd.</rights><rights>2009 © Expert Reviews Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-e8d2c67e2c8c7af37e875a946ee3f6b9788cf85004f78bb4a76ab626856109fa3</citedby><cites>FETCH-LOGICAL-c511t-e8d2c67e2c8c7af37e875a946ee3f6b9788cf85004f78bb4a76ab626856109fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1586/erv.09.19$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1586/erv.09.19$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>315,782,786,27931,27932,59654,60443</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19397417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barrett, P Noel</creatorcontrib><creatorcontrib>Mundt, Wolfgang</creatorcontrib><creatorcontrib>Kistner, Otfried</creatorcontrib><creatorcontrib>Howard, M Keith</creatorcontrib><title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines</title><title>Expert review of vaccines</title><addtitle>Expert Rev Vaccines</addtitle><description>The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.</description><subject>Animals</subject><subject>Avian influenza</subject><subject>Cell culture</subject><subject>Cell Culture Techniques</subject><subject>Cercopithecus aethiops</subject><subject>Contamination</subject><subject>continuous cell line</subject><subject>Diploids</subject><subject>Drug Approval</subject><subject>emerging virus disease</subject><subject>Epidemics</subject><subject>Fear</subject><subject>Humans</subject><subject>Infection</subject><subject>Influenza</subject><subject>Influenza A Virus, H5N1 Subtype - immunology</subject><subject>pandemics</subject><subject>Pediatrics</subject><subject>Rabies</subject><subject>Rabies virus</subject><subject>Rabies virus - immunology</subject><subject>Reviews</subject><subject>Rotavirus</subject><subject>Rotavirus - immunology</subject><subject>Smallpox</subject><subject>Smallpox - immunology</subject><subject>Smallpox vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vero</subject><subject>Vero Cells</subject><subject>viral vaccine</subject><subject>Viral Vaccines - biosynthesis</subject><subject>Viral Vaccines - genetics</subject><issn>1476-0584</issn><issn>1744-8395</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1v1DAQhiMEoqVw4A-giAOCQxY78WdvVUULUiUuwIGLNXHGrSsnXuxkq_57vMoiPoV8sGU9z8w7mqp6TsmGciXeYtptiN5Q_aA6ppKxRnWaPyxvJkVDuGJH1ZOcbwnpmObycXVEdaclo_K4-voFU6wthlBvA8wuprH2U70Da_2E9TbFYbGzj9NpPcadn67rOd5BGvLq2CXMS8Kmh4xDvfMJwg83P60eOQgZnx3uk-rzxbtP5--bq4-XH87PrhrLKZ0bVENrhcTWKivBdRKV5KCZQOyc6LVUyjrFCWFOqr5nIAX0ohWKC0q0g-6kerXWLWG_LZhnM_q8TwcTxiUbIamkTOgCvv4vSFsuJReE7NGXf6C3cUlTGcNQrXXLlCAF2qzQNQQ0fnJxTmDLGXD0Nk7ofPk_a1vBOVWKFeHNKtgUc07ozDb5EdK9ocTsN2nKJg3RpUdhXxwSLP2Iw0_ysLoCsBXYN04j3MUUBjPDfYjJJZisz6b7V93uN-0GIcw3FhL-MuJf1ncu7b1C</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Barrett, P Noel</creator><creator>Mundt, Wolfgang</creator><creator>Kistner, Otfried</creator><creator>Howard, M Keith</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><general>Expert Reviews Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines</title><author>Barrett, P Noel ; Mundt, Wolfgang ; Kistner, Otfried ; Howard, M Keith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-e8d2c67e2c8c7af37e875a946ee3f6b9788cf85004f78bb4a76ab626856109fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Avian influenza</topic><topic>Cell culture</topic><topic>Cell Culture Techniques</topic><topic>Cercopithecus aethiops</topic><topic>Contamination</topic><topic>continuous cell line</topic><topic>Diploids</topic><topic>Drug Approval</topic><topic>emerging virus disease</topic><topic>Epidemics</topic><topic>Fear</topic><topic>Humans</topic><topic>Infection</topic><topic>Influenza</topic><topic>Influenza A Virus, H5N1 Subtype - immunology</topic><topic>pandemics</topic><topic>Pediatrics</topic><topic>Rabies</topic><topic>Rabies virus</topic><topic>Rabies virus - immunology</topic><topic>Reviews</topic><topic>Rotavirus</topic><topic>Rotavirus - immunology</topic><topic>Smallpox</topic><topic>Smallpox - immunology</topic><topic>Smallpox vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vero</topic><topic>Vero Cells</topic><topic>viral vaccine</topic><topic>Viral Vaccines - biosynthesis</topic><topic>Viral Vaccines - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrett, P Noel</creatorcontrib><creatorcontrib>Mundt, Wolfgang</creatorcontrib><creatorcontrib>Kistner, Otfried</creatorcontrib><creatorcontrib>Howard, M Keith</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert review of vaccines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrett, P Noel</au><au>Mundt, Wolfgang</au><au>Kistner, Otfried</au><au>Howard, M Keith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines</atitle><jtitle>Expert review of vaccines</jtitle><addtitle>Expert Rev Vaccines</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>8</volume><issue>5</issue><spage>607</spage><epage>618</epage><pages>607-618</pages><issn>1476-0584</issn><eissn>1744-8395</eissn><abstract>The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>19397417</pmid><doi>10.1586/erv.09.19</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-0584 |
| ispartof | Expert review of vaccines, 2009-05, Vol.8 (5), p.607-618 |
| issn | 1476-0584 1744-8395 |
| language | eng |
| recordid | cdi_proquest_journals_199924860 |
| source | MEDLINE; Access via Taylor & Francis |
| subjects | Animals Avian influenza Cell culture Cell Culture Techniques Cercopithecus aethiops Contamination continuous cell line Diploids Drug Approval emerging virus disease Epidemics Fear Humans Infection Influenza Influenza A Virus, H5N1 Subtype - immunology pandemics Pediatrics Rabies Rabies virus Rabies virus - immunology Reviews Rotavirus Rotavirus - immunology Smallpox Smallpox - immunology Smallpox vaccine Vaccines Vaccines, Attenuated - immunology Vaccines, Inactivated - immunology Vero Vero Cells viral vaccine Viral Vaccines - biosynthesis Viral Vaccines - genetics |
| title | Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T15%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vero%20cell%20platform%20in%20vaccine%20production:%20moving%20towards%20cell%20culture-based%20viral%20vaccines&rft.jtitle=Expert%20review%20of%20vaccines&rft.au=Barrett,%20P%20Noel&rft.date=2009-05-01&rft.volume=8&rft.issue=5&rft.spage=607&rft.epage=618&rft.pages=607-618&rft.issn=1476-0584&rft.eissn=1744-8395&rft_id=info:doi/10.1586/erv.09.19&rft_dat=%3Cgale_proqu%3EA226551884%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199924860&rft_id=info:pmid/19397417&rft_galeid=A226551884&rfr_iscdi=true |